

U.S. National Phase of PCT/FR99/02913

Clean Version of Claims

1. (Amended) A vaccine comprising:
 - less than 1.2 mg per ml of an aluminum salt, wherein the amount is expressed with respect to the aluminum atom, and
 - immunogenic antigens of poliovirus, *Corynebacterium diphtheriae* and *Clostridium tetani*, wherein the amount of the *Corynebacterium diphtheriae* immunogenic antigen is 4-16 Lf per ml.
2. (Amended) The vaccine as claimed in claim 1, wherein the amount of diphtheria immunogenic antigen is about 10 Lf per ml.
3. (Amended) The vaccine as claimed in claim 1, wherein the amount of tetanus immunogenic antigen is about 20 Lf per ml.
4. (Amended) The vaccine as claimed in claim 1, further comprising at least one antigen selected from the group consisting of *Bordetella pertussis*, hepatitis A and hepatitis B antigens.
9. (Amended) A pharmaceutical kit comprising at least 2 injectable doses of the vaccine as claimed in claim 1.
10. (Amended) A method for immunizing a human against at least poliovirus, *Corynebacterium diphtheriae* and *Clostridium tetani*, the method comprising administering to the person a vaccine as claimed in claim 1.

11. (Amended) The method as claimed in claim 10, wherein the vaccine is administered via deep subcutaneous or intramuscular injection in 3 doses, the first two doses being administered 1 to 2 months apart and the third dose being administered 6 to 12 months after the injection of the second dose.
12. (Amended) The method as claimed in claim 10, wherein the vaccine is administered via deep subcutaneous or intramuscular injection in one dose or in two doses at least 1 month apart.